News

July 2009
Cytogel Pharma announces the successful completion of the pre-clinical program for its novel analgesic compound, Cyt-1010, a member of a new class of drugs based on the endomorphins. With its unique chemical structure, it is distinct from other peptides and opioids. The data from the pre-clinical program have demonstrated very good activity and a favorable safety profile. The IND application for Cyt-1010 is now in preparation.